HNB
AKTX

Huntington National Bank’s Akari Therapeutics AKTX Stock Holding History

Huntington National Bank’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10
Closed -$35K – 1560
2017
Q4 		$35K Hold
10
– – ﹤0.01% 1063
2017
Q3 		$49K Buy
+10
New +$37.5K ﹤0.01% 985

Other funds holding AKTX

HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Huntington National Bank's AKTX Position: Q1 2018 in Review

Huntington National Bank sold out of Akari Therapeutics (AKTX) in Q1 2018, closing a stake of 10 shares — an estimated $35K sold.

Huntington National Bank first reported a position in AKTX in Q3 2017 and held it in 2 quarters. The position peaked at $49K in Q3 2017. 9 funds tracked by Wall St. Rank hold AKTX as of Q1 2018.

  • Huntington National Bank reported no remaining Akari Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Huntington National Bank sold 10 Akari Therapeutics shares in Q1 2018, an estimated $35K.
  • Huntington National Bank first reported a position in Akari Therapeutics in Q3 2017 and held it in 2 quarters.
  • Huntington National Bank's Akari Therapeutics position peaked at $49K in Q3 2017.
  • 9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2018.

Based on Huntington National Bank's 13F filing for Q1 2018, filed 30 Apr 2018.